- Published at
- by manilatimes.net
neutral
neutral
News for Akari Therapeutics, Plc (AKTX)
- Published at
- by gurufocus.com
neutralneutralAkari Therapeutics Joins Webull Corporate Connect Service Platform
Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here BOSTON and LONDON,- Published at
- by seekingalpha.com
neutralneutralAkari Therapeutics appoints Torsten Hombeck as CFO (NASDAQ:AKTX)
Akari Therapeutics appoints Torsten Hombeck as Chief Financial Officer, effective December 16.- Published at
- by investing.com
mixedmixedU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% By Investing.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28%VST-WTAVSTSMCIPRFXNVDC34.SANVDA.MXNVDA.BANVDANVD.DEWMTD.BAWMTC.BAWMT.SNWMT.MXWMT.DEWMTWALMARTCL.SNAMZNCL.SNAMZN.SNAMZN.MXAMZNAMZ.DEUNHD.BASLNCFSLN.LSLNNKED.BANKECL.SNNKE.SNNKE.MXNKE.DENKE.BANKEMRNA.MXMRNAMMMD.BAMMMCL.SNMMMC34.SAMMM.SWMMM.SNMMM.MXMMM.DEMMMM1RN34.SAITU.DEINTU34.SAINTUINCYI1NC34.SAAKTX0JCT.L0J9P.L0A45.L- Published at
- by manilatimes.net
positivepositive- Published at
- by globenewswire.com
positivepositiveAkari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced...- Published at
- by gurufocus.com
positivepositive- Published at
- by investing.com
positivepositiveAkari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights By Investing.com
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights- Published at
- by globenewswire.com
positivepositiveAkari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s...- Published at
- by globenewswire.com
positivepositiveAkari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic...- Published at
- by marketscreener.com
neutralneutralAkari Therapeutics : 2023 Annual Report
AKARI THERAPEUTICS, PLC ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 ...- Published at
- by investing.com
positivepositiveAkari Therapeutics secures $7.6 million in private financing By Investing.com
Akari Therapeutics secures $7.6 million in private financing- Published at
- by marketscreener.com
mixedmixedSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX -March 18, 2024 at 10:53 pm EDT
NEW YORK, March 18, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...- Published at
- by globenewswire.com
positivepositiveSHAREHOLDER ALERT: The M&A Class Action Launches Investigation of the Merger – SDPI, MINM, SCX, AKTX
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of Monteverde & Associates PC (the “M&A Class Action...- Published at
- by globenewswire.com
mixedmixedSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...- Published at
- by globenewswire.com
mixedmixedINVESTIGATION UPDATE: Halper Sadeh LLC Investigates IGT, AKTX, SDPI, VIVK
NEW YORK, March 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...- Published at
- by globenewswire.com
mixedmixedAkari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...- Published at
- by globenewswire.com
mixedmixedPresenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now
MIAMI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 63rd...- Published at
- by medium.com
mixedmixedGlobal Guillain Barr syndrome treatment Market Opportunities, Past, Present Data And Forecast 2027
Global Guillain Barr syndrome treatment Market Opportunities, Past, Present Data And Forecast 2027. Deep insights into worldwide market revenue, parent market trends, macroeconomic indicators, governing variables, market attractiveness per….- Published at
- by etfdailynews.com
mixedmixedAnalysts’ New Coverage for May 29th (AACG, AAME, ABEO, ACOR, ACRX, ACU, AEMD, AEY, AEZS, AGFS)
Read Analysts’ New Coverage for May 29th (AACG, AAME, ABEO, ACOR, ACRX, ACU, AEMD, AEY, AEZS, AGFS) at ETF Daily NewsXELBWVVIWNEBWHLMVTVTULBIUBFOTTOOTTNPTSBKTRIBTRECTENXTEDUSYPRSVVCSUMRSTRMSREVSOHOSNFCASMMTSIEBSFESBFGSALRVSBRNWKRMTIRMCFRGLSRGCORDIRAVEQUMUQUIKPWODPWFLPULMPRPHPPBBPFIEPEBKPDEXPCTIPBPBOVLYOVBCOBCINYMXNWFLNVCNNTWKNTICNHNERVNEPTNAIIMPXMCHXMBCNMACKLWAYLEDSLARKKTCCITCBITAUCORP.SNIRSA.BAIRSIRIXIPDNIHTIDRAHZNHWBKHLGHBPHALLGTIMGSITGNCAGIGMGHMGENCGASSFWPFUNCFSFGFORDFNWBFENGFCCOFCAPFANHEVOKEVKESSAEMLEDUCEBMTDYNTDXYNDTEADCTHCYDCYCCCVVCVLYCTHRCPIXCORRCOECNETCMCMCLSNCLROCLRBCLIRCJJDCHNRCHMGCHCICGIXCFMSCFFICEMICDTXCBFVCAASBYFCBLPHBLCMBGSFBBGIAUTOASURASTCARLARKRAPAMSALOTALIMAKTXAIRIAGFSAEZSAEYAEMDACRXACORABEOAAMEAACGCGACFRX